|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.74 AUD | +0.29% |
|
-7.22% | -44.17% |
| Capitalization | 4.65B 3.09B 2.63B 2.46B 2.31B 4.26B 280B 28.7B 11.13B 132B 11.6B 11.35B 481B | P/E ratio 2025 * |
152x | P/E ratio 2026 * | 64.7x |
|---|---|---|---|---|---|
| Enterprise value | 5.03B 3.34B 2.85B 2.66B 2.5B 4.61B 303B 31.05B 12.04B 143B 12.54B 12.28B 521B | EV / Sales 2025 * |
4.05x | EV / Sales 2026 * | 3.49x |
| Free-Float |
58.65% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Telix Pharmaceuticals Limited
| 1 day | +0.29% | ||
| 1 week | -7.22% | ||
| Current month | -9.72% | ||
| 1 month | -7.97% | ||
| 3 months | +0.37% | ||
| 6 months | -46.43% | ||
| Current year | -44.17% |
| 1 week | 13.46 |  | 15.01 |
| 1 month | 13.46 | | 15.4 |
| Current year | 13.3 | | 31.97 |
| 1 year | 13.3 | | 31.97 |
| 3 years | 5.82 | | 31.97 |
| 5 years | 3.41 | | 31.97 |
| 10 years | 0.46 | | 31.97 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 03/01/2017 | |
Darren Smith
DFI | Director of Finance/CFO | 60 | 31/07/2022 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 50 | 03/01/2017 | |
Mark Nelson
BRD | Director/Board Member | 65 | 17/09/2017 |
Jann Skinner
BRD | Director/Board Member | 67 | 19/06/2018 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.29% | -7.22% | -43.01% | +105.07% | 3.09B | |
| -1.79% | -5.23% | -6.09% | +11.09% | 45.43B | |
| -1.65% | -1.59% | +10.92% | +4.28% | 37.85B | |
| -0.55% | -1.19% | +76.99% | +56.17% | 35.31B | |
| +0.05% | +1.91% | +10.32% | +20.20% | 27.66B | |
| -1.46% | +1.78% | +60.58% | +164.03% | 15.72B | |
| +0.52% | -0.90% | +75.65% | +231.60% | 15.26B | |
| -1.76% | +0.38% | -11.49% | -5.32% | 14.25B | |
| -4.40% | -7.89% | +68.16% | - | 12.56B | |
| +4.88% | +7.29% | +68.72% | +79.89% | 13.47B | |
| Average | -0.36% | -1.47% | +31.08% | +74.11% | 22.06B | |
| Weighted average by Cap. | -0.73% | -1.58% | +30.52% | +51.17% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.24B 825M 703M 657M 618M 1.14B 74.76B 7.67B 2.97B 35.24B 3.1B 3.03B 129B | 1.45B 962M 819M 765M 720M 1.33B 87.1B 8.93B 3.46B 41.06B 3.61B 3.53B 150B |
| Net income | 33.6M 22.31M 19.01M 17.75M 16.7M 30.75M 2.02B 207M 80.38M 953M 83.72M 81.95M 3.48B | 112M 74.28M 63.28M 59.11M 55.62M 102M 6.73B 690M 268M 3.17B 279M 273M 11.57B |
| Net Debt | 381M 253M 215M 201M 189M 348M 22.9B 2.35B 911M 10.79B 949M 929M 39.38B | 405M 269M 229M 214M 201M 370M 24.34B 2.5B 968M 11.47B 1.01B 987M 41.86B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 13.74 $ | +0.29% | 1,545,878 |
| 11/12/25 | 13.70 $ | -2.14% | 1,988,417 |
| 10/12/25 | 14.00 $ | -2.23% | 1,747,621 |
| 09/12/25 | 14.32 $ | -1.85% | 1,027,596 |
| 08/12/25 | 14.59 $ | -1.49% | 957,193 |
Delayed Quote Australian S.E., 12 December 2025 at 04:10 pm AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TLX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition